natgillin/translations-raw huggingface dataset:
- 0.4 mL in a 1 mL graduated syringe for Somatropin Biopartners 2 mg - 0.6 mL in a 1 mL graduated syringe for Somatropin Biopartners 4 mg - 0.9 mL in a 1 mL graduated syringe for Somatropin Biopartners 7 mg
- 0,4 ml u graduiranoj štrcaljki od 1 ml za Somatropin Biopartners 2 mg - 0,6 ml u graduiranoj štrcaljki od 1 ml za Somatropin Biopartners 4 mg - 0,9 ml u graduiranoj štrcaljki od 1 ml za Somatropin Biopartners 7 mg
Turn the vial upside down, with the syringe in and place the tip of the needle in the suspension as shown in figure 9.
Okrenite bočicu s uvedenom štrcaljkom naopako i postavite vršak igle u suspenziju kako je prikazano na slici 9.
Long term carcinogenicity studies with Somatropin Biopartners have not been conducted.
Nisu provedena dugotrajna ispitivanja kancerogenosti Somatropina Biopartners.
Important information about some of the ingredients of Somatropin Biopartners
Važne informacije o nekim sastojcima Somatropina Biopartners
Uncommon, may affect up to 1 in 100 people - enlargement of the male breast
Manje često, mogu se javiti u do 1 na 100 osoba - povećanje dojki kod muškaraca
The following adverse reactions have been observed under treatment with Somatropin Biopartners in a 6-month controlled clinical study with 151 adult patients with GHD of adult or childhood-onset and in a 6-month extension study.
Opažene su sljedeće nuspojave tijekom liječenja Somatropinom Biopartners u 6-mjesečnom kontroliranom kliničkom ispitivanju u 151 odraslih bolesnika s NHR nastalim u odrasloj dobi ili djetinjstvu i u 6-mjesečnom produžetku ispitivanja.
Insert the needle straight through the centre of the vial's rubber stopper into the suspension.
Uvedite iglu ravno kroz sredinu gumenog čepa na bočici u suspenziju.
These patients should be counselled on risks before initiating therapy.
Prije početka terapije ovi bolesnici moraju biti obaviješteni o rizicima.
Dosage reductions may be necessary: - in patients above 60 years of age - in patients who develop long lasting tissue swelling caused by fluid retention or who develop abnormal sensations such as prickling, tingling and itchiness - to avoid the development of carpal tunnel syndrome, where the nerve running through the wrist
Sniženje doze može biti potrebno: - u bolesnika starijih od 60 godina - u bolesnika koji razviju dugotrajni otok tkiva prouzročen zadržavanjem tekućine ili koji razviju abnormalne senzacije kao što su bockanje, trnci i svrbež - da bi se izbjegao razvoj sindroma karpalnog kanala, gdje dolazi do pritiska na živac koji prolazi kroz zapešće (živac medijanus), što dovodi do utrnulosti i bola u šaci - nakon primjene lijeka tijekom produljenog vremenskog razdoblja, osobito u muškaraca.
Common: Impaired fasting glucose, hyperlipidaemia, increased blood insulin, increased blood cholesterol, decreased blood sodium, increased blood triglycerides, increased blood glucose, increased or decreased HDL, increased LDL
Često: oštećenje tolerancije glukoze natašte, hiperlipidemija, povišen inzulin u krvi, povišen kolesterol u krvi, sniženi natrij u krvi, povišeni trigliceridi u krvi, povišena glukoza u krvi, povišen ili snižen HDL, povišen LDL
Common: Decreased or increased white blood cell count, increased glycosylated haemoglobin, decreased haemoglobin
Često: smanjeni ili povećani broj bijelih krvnih stanica, povećani glikozilirani hemoglobin, sniženi hemoglobin
Somatropin Biopartners is not recommended during pregnancy.
Ne preporučuje se koristiti Somatropin Biopartners tijekom trudnoće.
Clean the injection site with an unused alcohol swab.
Očistite mjesto za injekciju pomoću nove vatice natopljene alkoholom.
IGF-I SDS in the range of +1 to +2
IGF-I SDS u rasponu od +1 do +2
Somatropin Biopartners is indicated in children and adolescents aged 2 to 18 years for long-term treatment of growth failure due to insufficient secretion of endogenous growth hormone.
Somatropin Biopartners je indiciran u djece i adolescenata u dobi od 2 do 18 godina za dugotrajno liječenje zastoja u rastu zbog nedovoljnog izlučivanja endogenog hormona rasta.
The following adverse reactions have been observed under treatment with Somatropin Biopartners in a 12-month controlled comparative clinical study in 178 treatment naïve children with growth failure due to insufficient secretion of endogenous growth hormone and in a dose finding study.
Opažene su sljedeće nuspojave tijekom liječenja Somatropinom Biopartners u 12-mjesečnom kontroliranom usporednom kliničkom ispitivanju u 178 djece koja prethodno nisu bila liječena i imaju zastoj u rastu zbog nedostatnog lučenja endogenog hormona rasta i u ispitivanju pronalaženja doze.
After reconstitution the medicinal product should be used immediately before the suspension settles.
Nakon rekonstitucije, lijek treba primijeniti odmah prije nego što se suspenzija slegne.
Adults with childhood-onset of GHD
Odrasli s NHR nastalim u djetinjstvu
After reconstitution the injection should be administered immediately.
Nakon rekonstitucije, injekcija se mora treba odmah primijeniti.
General disorders and administration site conditions Very common: Oedema peripheral, oedema (local and generalised)* Common: Fatigue, pain, asthenia, face oedema, local swelling, oedema, thirst, malaise, chest pain, increased weight, injection site pain
Vrlo često: periferni edemi, edemi (lokalni i generalizirani)* Često: umor, bol, astenija, edem lica, lokalni otok, edemi, žeđ, malaksalost, bol u prsištu, povećana tjelesna težina, bol na mjestu injekcije
In patients with an already manifest diabetes mellitus, the anti-diabetic therapy might require adjustment when somatropin treatment is initiated.
U bolesnika s već manifestnom šećernom bolešću moguća je prilagodba antidijabetičke terapije prilikom započinjanja terapije somatropinom.
Following repeated weekly subcutaneous administration of a mean dose of 4.4 mg prolonged release somatropin to adults with GHD the Cmax and tmax of plasma hGH were about 4.5 ng/mL and 15 h respectively.
Nakon ponovljene tjedne supkutane primjene srednje doze od 4,4 mg somatropina s produljenim oslobađanjem odraslima s NHR, Cmax ljudskog hormona rasta (hGH) u plazmi iznosio je oko 4,5 ng/ml, a tmax oko 15 sati.
Powder and solvent for prolonged-release suspension for injection 20 mg powder in a vial and 1.5 mL solvent in a vial 1 vial of 20 mg powder
Prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem 20 mg praška u bočici i 1,5 ml otapala u bočici 1 bočica s 20 mg praška
Information about self-injection of Somatropin Biopartners
Informacije o samoubrizgavanju Somatropina Biopartners
Apply gentle pressure to the injection site with a dry gauze or cotton pad.
Lagano pritisnite mjesto injekcije suhom gazom ili vaticom.
4 vials of 10 mg powder
4 bočice s 10 mg praška
For the treatment of children and adolescents aged 2 to 18 years the 10 mg and 20 mg vials of this medicinal product should be used.
Za liječenje djece i adolescenata u dobi od 2 do 18 godina moraju se koristiti bočice od 10 mg i 20 mg ovog lijeka.
Common: Nausea
Često: mučnina
Very common: Mild hyperglycaemia*
Vrlo često: blaga hiperglikemija*
In children, Somatropin Biopartners should be administered subcutaneously at a concentration of 20 mg/mL.
U djece se Somatropin Biopartners mora primijeniti potkožno u koncentraciji od 20 mg/ml.
Apply gentle pressure to the plunger to get rid of the bubbles.
Primijenite lagani pritisak na klip kako biste uklonili mjehuriće.
The plunger should be pushed up gently, until all bubbles are removed from the syringe and needle.
Klip treba nježno potiskiati sve dok se ne uklone svi mjehurići iz štrcaljke i igle.
*produced in Saccharomyces cerevisiae by recombinant DNA technology For the full list of excipients, see section 6.1.
*proizvedeno u kvascu Saccharomyces cerevisiae pomoću tehnologije rekombinantne DNK
After preparation, the product must be used immediately.
Nakon pripreme, lijek se mora odmah primijeniti.
Following repeated weekly subcutaneous administration of a mean dose of 0.5 mg/kg prolonged release somatropin to prepubertal children with GHD the Cmax and tmax of plasma hGH were about 60.7 ng/mL and 12.0 h respectively.
Nakon ponovljene tjedne supkutane primjene srednje doze od 0,5 mg/kg somatropina s produljenim oslobađanjem predpubertskoj djeci s NRH, Cmax hGH u plazmi iznosio je oko 60,7 ng/ml, a tmax oko 12,0 sati.
Common, may affect up to 1 in 10 people - virus infection known as Herpes simplex - skin tag (a form of harmless skin growth) - tiredness - weakness, feeling unwell - face swelling - thirst - pain, chest pain, pain at the injection site - pain in the back, arms, legs, shoulders, bones, joints - sleeplessness - decreased sensation, numbness and tingling in fingers and palm of the hand due to squeezed nerve at wrist (carpal tunnel syndrome) - dizziness, sleepiness - muscular or bone stiffness, weakness of the muscles, muscle pain, feeling of heaviness - inflammation of the tendons, joint swelling, joint inflammation - reddening of the eyes, reduced vision, vertigo (a feeling of dizziness or spinning) - increased or irregular heart rate - high blood pressure - nosebleed - nausea - increased level of bilirubin, a substance produced by the liver - inflammation of the gall bladder - acne, increased sweating, skin rash - allergic skin reactions such as redness, irritation, itching - blood in the urine - nipple pain - reduced function of the adrenal gland (which could show as tiredness) - reduced function of the thyroid gland - increased fat levels in the blood - weight gain - development of substances (antibodies) in the blood that bind to growth hormone - changes in blood test results such as a change in the number of white blood cells or increased levels of insulin, sugar, sodium or certain fatty substances in the blood - changes in liver test results - a type of benign brain tumour called craniopharyngioma
Često, mogu se javiti u do 1 na 10 osoba - infekcija virusom koji se zove Herpes simplex - kožni fibromi (oblik bezopasne izrasline na koži) - umor - slabost, loše osjećanje - otok lica - žeđ - bol, bol u prsištu, bol na mjestu injekcije - bol u leđima, rukama, nogama, ramenima, kostima, zglobovima - nesanica - smanjen osjet, utrnulost i trnci u prstima i dlanovima zbog pritisnutog živca u zapešću (sindrom karpalnog kanala) - omaglica, pospanost - mišićna ili koštana ukočenost, slabost mišića, mišićni bol, osjećaj težine - upala tetiva, otok zglobova, upala zglobova - crvenilo očiju, oslabljen vid, vrtoglavica (osjećaj omaglice ili vrtnje) - ubrzan ili nepravilan rad srca - povišen krvni tlak - krvarenje iz nosa - mučnina - povišena razina bilirubina, tvari koju proizvodi jetra - upala žučnog mjehura - akne, pojačano znojenje, kožni osip - alergijska kožna reakcija, kao što je crvenilo, nadraženost, svrbež - krv u mokraći - bol u bradavicama - smanjena funkcija nadbubrežne žlijezde (koja se može očitovati kao umor) - smanjena funkcija štitne žlijezde - povišene razine masnoća u krvi - povećanje tjelesne težine - razvoj tvari (protutijela) u krvi koje se vežu na hormon rasta - promjene u rezultatima krvnih pretraga kao što je promjena broja bijelih krvnih stanica ili povišene razine inzulina, šećera, natrija ili određenih masnih tvari u krvi - promjene u rezultatima jetrenih pretraga - vrsta dobroćudnog tumora mozga koji se zove kraniofaringeom
Somatropin Biopartners 10 mg is sufficient for use in children up to 20 kg bodyweight.
Somatropin Biopartners 10 mg dovoljan je za primjenu u djece tjelesne težine do 20 kg.
For the treatment of children and adolescents aged 2 to 18 years vials with 10 mg and 20 mg somatropin should be used.
Za liječenje djece i adolescenata u dobi od 2 do 18 godina moraju se koristiti bočice s 10 mg i 20 mg somatropina.
Apply gentle pressure by pushing the plunger up, until all bubbles are removed from the syringe and needle.
Nježnim pritiskom potisnite klip prema gore, sve dok svi mjehurići ne budu uklonjeni iz štrcaljke i igle.
Contact your doctor if this happens.
Ako se to dogodi, obratite se liječniku.
Somatropin Biopartners 20 mg is sufficient for use in children up to 40 kg bodyweight.
Somatropin Biopartners 20 mg dovoljan je za primjenu u djece tjelesne težine do 40 kg.
Psychiatric disorders Very rare: insomnia*
Vrlo rijetko: nesanica*
The syringe should be filled with the correct volume of the solvent for injection as listed above and the syringe needle withdrawn from the vial subsequently.
Štrcaljku treba napuniti ispravnim volumenom otapala za injekciju kako je navedeno gore i iglu štrcaljke nakon toga izvući iz bočice.
Uncommon: Gynaecomastia*
Vrlo rijetko: ginekomastija*
Common, may affect up to 1 in 10 people - tiredness or weight gain due to underactive thyroid gland - reduced function of the adrenal gland (which may show as tiredness) - mild blood sugar increase - headache, lethargy (lack of energy), dizziness - vomiting, stomach ache - discoloration of the skin - pain in joints, arms or legs - pain, discoloration, swelling, hardening, reddening or feeling of warmth at the injection site - tissue swelling - fever - changes in blood levels of certain hormones
Često, mogu se javiti u do 1 na 10 osoba - umor ili povećanje tjelesne težine zbog smanjene aktivnosti štitne žlijezde - smanjena funkcija nadbubrežne žlijezde (što se može očitovati kao umor) - blago povišen šećer u krvi - glavobolja, letarija (nedostatak energije), omaglica - povraćanje, bol u želucu - promjena boje kože - bol u zglobovima, rukama ili nogama - bol, promjena boje, otok, otvrdnuće, crvenilo ili žarenje na mjestu injekcije - otok tkiva - vrućica - promjene razine određenih hormona u krvi
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).
Lijek se izdaje na ograničeni recept (vidjeti Dodatak I: Sažetak opisa svojstava lijeka, dio 4.2).
No clinical studies have been conducted with Somatropin Biopartners in breast-feeding women.
Nisu provedena klinička ispitivanja Somatropin Biopartnersa u dojilja.
A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
PROIZVOĐAČ(I) BIOLOŠKE(IH) DJELATNE(IH) TVARI I PROIZVOĐAČ(I) ODGOVORAN(ODGOVORNI)ZA PUŠTANJE SERIJE LIJEKA U PROMET
The other ingredients are sodium hyaluronate, egg phospholipids, sodium dihydrogen phosphate anhydrous and disodium phosphate anhydrous.
Drugi sastojci su natrijev hijaluronat, fosfolipidi jaja, natrijev dihidrogenfosfat bezvodni i natrijev hidrogenfosfat bezvodni.
Somatropin Biopartners 2 mg powder and solvent for prolonged-release suspension for injection Somatropin Biopartners 4 mg powder and solvent for prolonged-release suspension for injection Somatropin Biopartners 7 mg powder and solvent for prolonged-release suspension for injection
Somatropin Biopartners 2 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem Somatropin Biopartners 4 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem Somatropin Biopartners 7 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem
Do not use Somatropin Biopartners
Nemojte primjenjivati Somatropin Biopartners
1 vial of 1.5 mL solvent
1 bočica s 1,5 ml otapala
For storage conditions of the reconstituted medicinal product, see section 6.3.
Uvjete čuvanja nakon rekonstitucije lijeka vidjeti u dijelu 6.3.
Metabolism and nutrition disorders Common: Mild hyperglycaemia* Not known: Insulin resistance*
Često: blaga hiperglikemija* Nepoznato: inzulinska rezistencija*
Continue to fill the syringe with the correct volume of the solvent for injection, as described in the text of figure 4 above.
Nastavite puniti štrcaljku ispravnim volumenom otapala za injekciju, kako je opisano u tekstu iznad slike 4. Izvucite iglu štrcaljke iz bočice.
Common: Tachycardia, heart rate abnormal/irregular Vascular disorders
Često: tahikardija, abnormalan/nepravilan rad srca
Withdraw the syringe from the vial.
Izvucite štrcaljku iz bočice.
The syringe should be filled with a volume of air equal to the required volume of the solvent for injection and the air injected into the solvent vial to make it easier to withdraw the solvent.
Štrcaljku treba napuniti volumenom zraka koji je jednak potrebnom volumenu otapala za injekciju i ubrizgati taj zrak u bočicu s otapalom da se olakša izvlačenje otapala.
Oral oestrogen administration increases the dose requirements in women.
Kod primjene peroralnog estrogena u žena potrebna je veća doza.
Somatropin Biopartners should be administered subcutaneously at a concentration of 10 mg/mL.
Somatropin Biopartners mora se primijeniti supkutano u koncentraciji od 10 mg/ml.
Infections and infestations Common: Herpes simplex
Često: herpes simpleks
Vascular disorders Rare: hypertension*
Rijetko: hipertenzija*
If you forget to use Somatropin Biopartners
Ako ste zaboravili primijeniti Somatropin Biopartners
Talk to your doctor before using Somatropin Biopartners if you: - are an adult who has been treated with growth hormone during childhood: Your doctor will re-examine you for lack of growth hormone before restarting/continuing treatment; - have a hereditary disease called Prader-Willi syndrome: You should not be treated with this medicine unless you also have a lack of growth hormone; - have had a tumour: Your doctor will examine you frequently to ensure that the tumour has not come back; - have symptoms like severe and recurrent headache, visual changes, nausea and/or vomiting which may be due to increased pressure in the skull during growth hormone treatment; - suffer from an organic growth hormone deficiency (lack of growth hormone due to damage to the pituitary gland or the part of the brain called the hypothalamus) or decreased secretion of
Obratite se svom liječniku prije nego primijenite Somatropin Biopartners ako: - ste odrasla osoba koja se liječila hormonom rasta tijekom djetinjstva: Liječnik će Vas ponovno pregledati na nedostatak hormona rasta prije ponovnog početka/nastavka liječenja; - imate nasljednu bolest koja se zove Prader-Willijev sindrom: Ne smijete se liječiti ovim lijekom osim ako nemate i nedostatak hormona rasta; - ako ste imali tumor: Liječnik će Vas često pregledavati kako bi osigurao da se tumor nije vratio; - imate simptome poput teške i ponavljajuće glavobolje, promjena vida, mučnine i/ili povraćanja, koji mogu biti posljedica povišenja tlaka u glavi tijekom liječenja hormonom rasta; - bolujete od organskog nedostatka hormona rasta (nedostatak hormona rasta zbog oštećenja hipofize ili dijela mozga koji se zove hipotalamus) ili smanjenog izlučivanja hormona hipofize: Liječnik će Vam provjeriti razine hormona nadbubrežne žlijezde (glukokortikoida), koji mogu zahtijevati prilagodbu prije nego što počne terapija hormonom rasta.
Insert the needle through the centre of the rubber stopper of the solvent vial and inject all of the air into the vial.
Uvedite iglu kroz sredinu gumenog čepa na bočici s otapalom i ubrizgajte sav zrak u bočicu.
If you stop using Somatropin Biopartners
Ako prestanete primjenjivati Somatropin Biopartners
Skin and subcutaneous tissue disorders Common: pigmentation disorder (1.1%)
Često: poremećaj pigmentacije (1,1%)
Talk to your doctor before using Somatropin Biopartners if you: - have a hereditary disease called Prader-Willi syndrome: You should not be treated with this medicine unless you also have a lack of growth hormone; - have had a tumour: Your doctor will examine you frequently to ensure that the tumour has not come back; - have symptoms like severe and recurrent headache, visual changes, nausea and/or vomiting which may be due to increased pressure in the skull during growth hormone treatment; - suffer from an organic growth hormone deficiency (lack of growth hormone due to damage to the pituitary gland or the part of the brain called the hypothalamus) or decreased secretion of
Obratite se svom liječniku prije nego primijenite Somatropin Biopartners ako: - imate nasljednu bolest koja se zove Prader-Willijev sindrom: Ne smijete se liječiti ovim lijekom osim ako nemate i nedostatak hormona rasta; - ako ste imali tumor: Liječnik će Vas često pregledavati kako bi osigurao da se tumor nije vratio: - imate simptome poput teške i ponavljajuće glavobolje, promjene vida, mučnine i/ili povraćanja, koji mogu biti posljedica povišenja tlaka u glavi tijekom liječenja hormonom rasta; - bolujete od organskog nedostatka hormona rasta (nedostatak hormona rasta zbog oštećenja hipofize ili dijela mozga koji se zove hipotalamus) ili smanjenog izlučivanja hormona hipofize: Liječnik će Vam provjeriti razine hormona nadbubrežne žlijezde (glukokortikoida), koji mogu zahtijevati prilagodbu prije nego što počne terapija hormonom rasta.
Clean the rubber stopper again with an unused alcohol swab.
Ponovno očistite gumeni čep novom vaticom natopljenom alkoholom.
IGF-I SDS in the range of -1 to +1 and more than 1 SDS increase from Baseline Maintain
IGF-I SDS u rasponu od -1 do +1 i porast više od 1 SDS od početne vrijednosti nema
Investigations Common: decreased blood cortisol (2.2%)
Često: snižen kortizol u krvi (2,2%) Opis odabranih nuspojava
Hepatobiliary disorders Common: Hyperbilirubinaemia, cholecystitis, liver test abnormal
Često: hiperbilirubinemija, kolecistitis, abnormalni rezultati jetrenih testova
The syringe should be held upright and gentle pressure applied to the plunger until a small drop of suspension appears at the end of the needle.
Štrcaljku treba držati uspravno i nježno potiskivati klip sve dok se na vršku igle ne pojavi kapljica.
Gently tap the syringe to remove small air bubbles.
Nježno kucnite po štrcaljki da biste uklonili mjehuriće zraka.
4 vials of 1.5 mL solvent
4 bočice s 1,5 ml otapala
The powder should be homogenously suspended in the injection vehicle prior to administration.
Prije primjene, prašak treba homogeno suspendirati u otapalu injekcije.
Use a 1 mL or 2 mL graduated syringe with a 19G or wider needle for withdrawing the solvent from its vial.
Uporabite graduiranu štrcaljku od 1 ml ili 2 ml s iglom od 19G ili širom za izvlačenje otapala iz bočice.
Powder: sodium hyaluronate, egg phospholipids, sodium dihydrogen phosphate anhydrous, disodium phosphate anhydrous.
Prašak: natrijev hijaluronat, fosfolipidi jaja, natrijev dihidrogenfosfat bezvodni, natrijev hidrogenfosfat bezvodni.
Use a 1 mL graduated syringe with a 19G or wider needle for withdrawing the solvent from its vial.
Uporabite graduiranu štrcaljku od 1 ml s iglom od 19G ili širom za izvlačenje otapala iz bočice.
Powder and solvent for prolonged-release suspension for injection.
Prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem.
Without touching the rubber top the vial should be swirled vigorously until the content is completely mixed.
Bez dodirivanja gumenog vrha bočicu treba žustro mućkati kružnim pokretima dok se sav sadržaj ne promiješa.
Neoplasms benign, malignant and unspecified (including cysts and polyps) Common: Neoplasm progression (1 case of neoplasm progression in a female patient with a history of neurofibromatosis and radiation treatment), acrochordon, craniopharyngioma
Često: napredovanje novotvorine (1 slučaj napredovanja novotvorine u bolesnice s anamnezom neurofibromatoze i radioterapije), viseći kožni fibrom, kraniofaringeom
To remove small air bubbles the syringe should be tapped gently.
Da bi se uklonili mjehurići zraka, treba nježno kucnuti po štrcaljki.
Apply gentle pressure to the plunger until a small drop of suspension appears at the end of the needle.
Nježno potisnite klip sve dok se na vršku igle ne pojavi kapljica suspenzije.
Common: Swelling face, acne, allergic dermatitis, hyperhidrosis, urticaria, rash Musculoskeletal and connective tissue disorders
Često: otok lica, akne, alergijski dermatitis, hiperhidroza, urtikarija, osip
For other doses vials with 4 or 7 mg somatropin are available.
Za druge doze dostupne su bočice s 4 ili 7 mg somatropina.
For other doses vials with 2 or 7 mg somatropin are available.
Za druge doze dostupne su bočice s 2 ili 7 mg somatropina.
The 20-mg vial contains an overfill of somatropin powder to allow the withdrawal of up to 20 mg (1 mL suspension) of somatropin when reconstituted.
Bočica s 20 mg sadrži nešto više somatropin praška kako bi se omogućilo izvlačenje do 20 mg (1 ml suspenzije) somatropina nakon rekonstitucije.